Monte Rosa reports positive Phase 1 data for MRT-8102 in GFORCE-1 study
Monte Rosa Therapeutics said its Phase 1 GFORCE-1 study of MRT-8102 in 108 obese subjects with elevated cardiovascular risk showed reductions in several inflammation and plaque-related markers, with no serious adverse events reported. The filing does not include revenue, earnings or guidance, and the results come from an early-stage study. The company plans to start several Phase 2 studies, with timing running from late 2026 to the first half of 2027.
Key points
- GFORCE-1 enrolled 108 subjects, randomized to MRT-8102 at 5 mg, 20 mg or 40 mg once daily, or placebo, with 4 weeks of dosing and 4 weeks of follow-up.
- NEK7 degradation had a median reduction of approximately 80% to 90% across all three dose levels.
- Treatment-emergent adverse events occurred in 33% of MRT-8102 participants and 30% of placebo participants; no serious adverse events were reported.
- Median lipoprotein(a) fell 24%; GFORCE-2 is expected to start in H1 2027 and GEMINI-1 in Q4 2026 or Q1 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.